Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
Vadim S. Koshkin, MD
Advancing Myasthenia Gravis (MG) Treatment Through Guideline Updates and Emerging Therapies
October 30, 2025
San Francisco, California
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Darren Brenner, MD
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
What’s New In Glaucoma?
Paul Petrakos, DO, MS
Justin Schweitzer, OD, FAAO
I. Paul Singh, MD
Sarah H. Van Tassel, MD
From Doctor-Speak to Patient-Speak: Bridging the Communication Gap
Luis A. Gonzalez, MD, MPH
Jeremiah Brown Jr., MD, MS, FASRS
Time Is Bone: Making the Case for Early Anabolic Treatment in Osteoporosis
Kendall Moseley, MD
Kenneth G. Saag, MD
Trial in Progress: Phase 3 MoonRISe-3 Study
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
Robert D. Suh, MD
Lea Azour, MD
Ashwin Basavaraj, MD
Managing Side Effects in FcRn Therapy: Best Practices for gMG
Vera Bril, MD
Nicholas J. Silvestri, MD
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Hans Katzberg, MD
Ocular to Generalized MG: How and Why the Disease Evolves
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
Acromegaly Care: Individualized Diagnosis and Management Strategies
July 13, 2025
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
Neelam Goyal, MD
Diagnostic Advances in gMG: Effective Tools and Techniques
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles
New Strategies for Individualizing Treatment in DME
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Jonathan Strober, MD
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
Chairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
Mazen Noureddin, MD, MHSc
What’s New in Glaucoma Therapy?
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.